V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Tria (Q34171212)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Tria |
scientific article |
Statements
1 reference
V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Tria (English)
1 reference
B S Graham
1 reference
D C Montefiori
1 reference
J Zhou
1 reference
J Zhou
1 reference
R A Bucco
1 reference
D H Schwartz
1 reference
L A Cavacini
1 reference
M R Posner
1 reference
1 August 1993
1 reference
1 reference
840-847
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference